PAPERS

Gene therapy is one of the most exciting fields of biopharma today, but plasmids pose serious challenges for innovation and drug development. WuXi’s acquisition of OXGENE means a fusion of expertise, helping to create an efficient means of developing plasmids on a large...

A new transfection-free helper system supports a high-yield manufacturing process for recombinant adeno-associated viruses (rAAV), raising the bar for producing safe, high-quality viral vectors at scale. To learn more about TESSA, evaluate it or discuss partnering to...

The concept of gene therapy arose initially during the 1960s and early 1970s. Turning that concept into a therapeutic reality has taken a tremendous amount of scientific discovery and pioneering manufacturing efforts. Today, nearly half a century later, gene and cell...

Gene therapy involves inserting a new section of DNA into a patient’s cells, often encoding a healthy gene to replace a disease-causing copy. This DNA is delivered by viral vectors which are usually built from plasmids. Plasmids are small sections of genetic material which...

As gene therapies become increasingly successful, companies are in a competitive race to deliver manufacturing technologies that can streamline large-scale production at reduced costs and faster turnaround times. However, plasmids, the building blocks of viral vectors,...

Insights into how to overcome common hurdles to manufacturing and developing gene therapy, including overcoming a reliance on plasmid technology, streamlining manufacturing processing, and more.

Viruses have evolved to invade host cells and hijack their cellular machinery to direct the replication and transcription of their own genomes. While these properties make viruses dangerous pathogens, they also make them ideal couriers for getting new DNA into a host cell...

Viruses invade host cells and hijack their cellular machinery to direct the replication and transcription of their own genome. This makes them dangerous pathogens as well as ideal couriers to transport new DNA into a host cell and ensure that it’s transcribed, reports Dr...

Advanced therapy manufacturers have taken the head start that Nature’s given them and used developments in genetic engineering, computational biology and bioinformatics to perfect the viral particle as a vector for therapeutic DNA and hasten the clinical success of...

CAR-T cell therapies have demonstrated tremendous success in relapsed or refractory haematological malignancies. Now therapeutics companies and academics alike are racing to break through the barrier of solid tumours, taking imaginative approaches to overcome the numerous...